Outcomes of Kawasaki Disease

Objectives: Kawasaki disease (KD) is an acute systemic vasculitis of unknown etiology. Coronary artery lesions (CAL) develop in 15% to 20% of untreated cases. Our objective was to evaluate demographic, clinical, and laboratory features and short-intermediate coronary artery outcomes of children with KD. Patients and Methods: Medical records of patients with KD were retrospectively identified. Clinical information and echocardiography, laboratory, and angiographic results were noted using a standardized form. Results: The study included 44 patients with a mean age of the 29.72 ± 21 months (ranging from 1 month to 9.5 years). There were 28 male and 16 female patients; 20 patients were diagnosed as having had incomplete KD. Four cases with atypical presentation were significantly older than children with complete and incomplete KD; 17 patients (38.6 %) had coronary artery aneurysm (CAA), which declined to 6.8% after intravenous immunoglobulin (IVIG) treatment. Time between fever and diagnosis and abnormal levels of hemoglobin and platelets were all associated with CAA. The children were followed up for a mean of 36.39 ± 19 months (with a maximum of 16 years). Angiographic evolution and regression of CALs have been observed in 14 (82.3%) patients. Three patients in whom CALs persisted did not receive IVIG therapy because of delayed diagnosis. Conclusions: Awareness of KD in children has led to an increase in the number of cases. Utility of IVIG treatment to reduce the coronary artery involvement in patients with delayed diagnoses should be discussed and considered. Long-term results are required to assess whether the KD represents a risk factor for coronary artery diseases seen during adulthood.

[1]  K. Yoon,et al.  Genetic Polymorphism of SMAD5 is Associated With Kawasaki Disease , 2014, Pediatric Cardiology.

[2]  R. Fukazawa Long-term prognosis of Kawasaki disease: increased cardiovascular risk? , 2010, Current opinion in pediatrics.

[3]  A. Anarat,et al.  Childhood vasculitides in Turkey: a nationwide survey , 2006, Clinical Rheumatology.

[4]  Walter R Wilson,et al.  Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Statement for Health Professionals From the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association , 2004, Pediatrics.

[5]  R. Holman,et al.  Kawasaki syndrome hospitalizations in the United States, 1997 and 2000. , 2003, Pediatrics.

[6]  R. Chang The incidence of Kawasaki disease in the United States did not increase between 1988 and 1997. , 2003, Pediatrics.

[7]  K. Durongpisitkul,et al.  Immunoglobulin Failure and Retreatment in Kawasaki Disease , 2003, Pediatric Cardiology.

[8]  T. Southwood,et al.  Incidence of Henoch-Schonlein purpura, Kawasaki disease, and rare vasculitides in children of different ethnic origins , 2002, The Lancet.

[9]  S. Colan,et al.  Aortic root dilation in Kawasaki disease. , 2001, The American journal of cardiology.

[10]  橋野 かの子 Re-treatment for immune globulin-resistant Kawasaki disease : a comparative study of additional immune globulin and steroid pulse therapy , 2001 .

[11]  D. Sherry,et al.  Initial intravenous gammaglobulin treatment failure in Kawasaki disease. , 2000, Pediatrics.

[12]  G. B. Aydın,et al.  Rheumatic heart disease prevalence among schoolchildren in Ankara, Turkey. , 1999, The Turkish journal of pediatrics.

[13]  J. Newburger,et al.  Intravenous gamma-globulin treatment and retreatment in Kawasaki disease. US/Canadian Kawasaki Syndrome Study Group. , 1998, The Pediatric infectious disease journal.

[14]  S. Shulman,et al.  Prevalence of coronary artery abnormalities in Kawasaki disease is highly dependent on gamma globulin dose but independent of salicylate dose. , 1997, The Journal of pediatrics.

[15]  K Hashino,et al.  Long-term consequences of Kawasaki disease. A 10- to 21-year follow-up study of 594 patients. , 1996, Circulation.

[16]  K. Durongpisitkul,et al.  The prevention of coronary artery aneurysm in Kawasaki disease: a meta-analysis on the efficacy of aspirin and immunoglobulin treatment. , 1995, Pediatrics.

[17]  M. Takano,et al.  Gallium-67 myocardial imaging for the detection of myocarditis in the acute phase of Kawasaki disease (mucocutaneous lymph node syndrome): the usefulness of single photon emission computed tomography. , 1987, British heart journal.

[18]  A. Lewis,et al.  Regression of coronary aneurysms in patients with Kawasaki syndrome. , 1987, Circulation.

[19]  J. Huhta,et al.  Treatment of Kawasaki syndrome with intravenous gamma globulin. , 1987, The New England journal of medicine.

[20]  J. Newburger,et al.  Clinical spectrum of Kawasaki disease in infants younger than 6 months of age. , 1986, The Journal of pediatrics.

[21]  H. Nakano,et al.  High incidence of aortic regurgitation following Kawasaki disease. , 1985, The Journal of pediatrics.

[22]  Katsuko Sato,et al.  HIGH-DOSE INTRAVENOUS GAMMAGLOBULIN FOR KAWASAKI DISEASE , 1983, The Lancet.

[23]  T. Kozuka,et al.  Histopathological study on right endomyocardial biopsy of Kawasaki disease. , 1980, British heart journal.

[24]  Y. Hamashima,et al.  Pathology of the heart in Kawasaki disease. , 1978, Pediatrics.

[25]  T. Kawasaki,et al.  [Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes in children]. , 1967, Arerugi = [Allergy].